CD19 and diffuse large B-cell lymphoma: The majority of FMC63 CAR-T cell clinical trials have been conducted on patients with B-ALL and NHLs including diffuse large B cell lymphoma (DLBCL), follicular lymphoma (FL), mantle cell lymphoma (MCL) and marginal zone lymphoma (MZL), due to their generally high and stable expression of CD19 (Table 1).